Palifermin, a recombinant human keratinocyte growth factor, is commonly given to prevent mucositis following autologous transplantation. In the allogeneic hematopoietic stem cell transplant (allo-HSCT) setting, safety and efficacy data are limited. We conducted a retrospective study in 251 patients undergoing allo-HSCT, 154 of whom received peritransplant palifermin. In all patients, palifermin significantly decreased the mean number of days of total parenteral nutrition (TPN, 13 vs 16 days, P ¼ 0.006) and patient-controlled analgesia (PCA, 6 vs 10 days, P ¼ 0.023), as well as the length of initial hospital stay (LOS, 32 vs 37 days, P ¼ 0.014). However, the effect of palifermin was only significant in patients who received a TBI-but not BU-based chemotherapy conditioning regimen. In TBI recipients, palifermin decreased the mean number of days of TPN (13 vs 17 days, Po0.001) and PCA (7 vs 12 days, P ¼ 0.033), and the length of stay (32 vs 38 days, P ¼ 0.001). Palifermin did not affect GVHD, graft failure or relapse. Therefore, in the largest analysis with this patient population to date, we demonstrate that palifermin is safe in allo-HSCT patients, decreases TPN and PCA use and decreases LOS following TBI-based but not chemotherapy-based allo-HSCT.
INTRODUCTION
Myeloablative allogeneic hematopoietic SCT (allo-HSCT) is an established treatment for hematologic malignancies. Mucositis, resulting from injury to epithelial cells lining the oral cavity and gastrointestinal tract, is a complication of both high-dose chemotherapy and radiation-based conditioning. Although the use of MTX for GVHD prophylaxis is thought to contribute to mucositis, the incidence of moderate or severe mucositis following a TBI-based myeloablative regimen has been reported to be 64%, even in the absence of MTX. 1 Although the severity can vary with conditioning regimens, allo-HSCT-associated mucositis can result in significant morbidity, including oral pain requiring narcotics for analgesia, anorexia requiring total parenteral nutrition (TPN), a prolonged hospital stay and possibly lifethreatening infections from translocated mucosal bacteria. [2] [3] [4] Keratinocyte growth factor is a 28-kDa endogenous protein in the fibroblast growth factor family that functions as a growth factor for epithelial cells. 5 Keratinocyte growth factor has an important role in healing the epithelium following injury. 6 Palifermin (Kepivance, Swedish Orphan Biovitrium) is a recombinant human keratinocyte growth factor that is more stable than endogenous keratinocyte growth factor because of the removal of 23 amino acids from its N terminus (product information). Preclinical data in mouse models have demonstrated that administration of palifermin is protective against chemotherapy and radiation-induced mucositis. [7] [8] [9] [10] Clinically, palifermin has been demonstrated to mitigate mucositis after chemotherapy and TBI-based autologous HSCT. 11, 12 On the basis of a phase III study in autologous transplant patients that demonstrated a decreased incidence and duration of World Health Organization grade III-IV mucositis following TBI conditioning, palifermin was approved by the FDA for the prevention of mucositis during autologous and allogeneic HSCT. There is, however, limited published experience with palifermin in the context of allo-HSCT. [13] [14] [15] To help determine whether palifermin is safe and efficacious following allo-HSCT, we performed a retrospective analysis of our experience with palifermin administered to adult patients undergoing a myeloablative T-cell-depleted (TCD) allo-HSCT for hematologic malignancies. The TCD setting was selected in order to study the effects of palifermin in the absence of MTX, which is routinely given for GVHD prophylaxis. Although TCD has not been commonly used in the US, recent positive multicenter data support a more widespread use. 16, 17 This study represents the largest published experience to date detailing palifermin use during allo-HSCT.
PATIENTS AND METHODS Patients
This is a retrospective study of all 251 adult patients who received a TCD allo-HSCT for the treatment of a hematologic malignancy at MSKCC between January 2004 and December 2009. In all, 154 patients received palifermin during this time period. The allocation of patients is illustrated in Figure 1 . Palifermin therapy was initiated in January 2006 after its approval by the FDA. After that date, all but three patients who underwent TBI-based allo-HSCT received palifermin as a standard of care. Recipients of chemotherapy-based allo-HSCT after January 2006 received palifermin either on a phase II clinical trial evaluating palifermin in recipients of a 1 chemotherapy-based TCD allo-HSCT (n ¼ 19) or at the discretion of the attending physician (n ¼ 58). The phase II protocol included patients with a diagnosis of myelodysplastic syndrome (MDS) or secondary AML. For patients not on protocol, the decision to administer palifermin was primarily driven by date of transplant as practice patterns of the service changed. For example, 64 of the 77 patients who received palifermin with chemotherapy-based transplants were transplanted between 16 June 2006 and 8 May 2009. Only nine patients received palifermin off protocol outside this time period. Follow-up was until 30 June 2010. Written informed consent for treatment was obtained from all patients. Approval for this retrospective review was obtained from the Institutional Review and Privacy Board. Eligibility criteria for transplant included the following: a diagnosis of a hematologic malignancy in a disease state appropriate for TCD transplantation; availability of a donor with a minimum of an 8/10 HLA match; the absence of active infection; and lack of coexisting cardiac, pulmonary, hepatic or renal dysfunction that would preclude administration of the myeloablative cytoreductive regimen. HLA matching was established by DNA sequence-specific oligonucleotide typing for HLA-A, -B, -Cw, -DQB1 and -DRB1 loci. Supportive care was as per MSKCC guidelines as previously described, [18] [19] [20] and was similar for the chemotherapy and TBI groups. Aside from the implementation of vancomycin as prophylaxis against oropharyngeal flora in 2005 and the initiation of palifermin use in 2006, supportive care did not change during our study period. For example, our standard practice has been to start TPN on day (d) þ 2 or þ 3 and continue until patients achieve a documented caloric intake of 1000 calories per day. In all, 88% of patients in the study were treated on this schedule. Only 12 patients (5%) were more than one day outside the standard start day with a range from d À 4 to d þ 5. The only two patients who started later than d þ 4 did not receive palifermin.
Transplantation plan
Patients either received a TBI-based or chemotherapy-based preparative regimen. [18] [19] [20] The decision to administer a TBI-based transplant vs chemotherapy-based transplant was dependent on both protocol availability and the BMT Service's discretion regarding the patient's ability to tolerate TBI. Either of the two TBI-based regimens were used: TBI 1375 cGy given in 11 fractions followed by two daily doses of thiotepa (5 mg/kg/day) and two daily doses of CY (60 mg/kg/day, 39 patients) starting after thiotepa, or five daily doses of fludarabine (25 mg/m 2 /day, 82 patients) beginning on the first day of thiotepa. 19, 20 Hyperfractionation was used to decrease the toxicity associated with the higher than standard dose of TBI. 21 The CY-based preparative regimen lasts for 8 days, whereas the fludarabine-based preparative regimen lasts for 9 days. The chemotherapy-based preparative regimen consisted of administering BU (0.8 mg/kg/day) every 6 h for 10 or 12 doses, Melphalan (70 mg/m 2 /day) for 2 doses and fludarabine (25 mg/m 2 /day) for 5 doses. 18 Patients treated before 15 October 2009 received 10 doses of BU, with the last 4 doses adjusted according to first dose pharmacokinetics. After that date, the dose of BU was increased to 12 doses, with the last 6 doses dose adjusted according to first dose pharmacokinetics. Both variations of this chemotherapy-based preparative regimen span 8 days.
T cells were removed from BM grafts by sequential soybean lectin agglutination and sheep RBC-rosette depletion (nine patients). 19 T-cell depletion of G-CSF-mobilized PBSCs was accomplished by positive selection of CD34 þ stem cells using the ISOLEX 300i Magnetic Cell Separator and subsequent sheep RBC-rosette depletion (231 patients), 20 or the positive selection of CD34 þ stem cells using the Miltenyi CliniMACS system without subsequent sheep RBC-rosette depletion (11 patients). 16 T-cell-depleted marrow or PBSC was infused within 24-48 h after completion of the chemotherapy. Conditioning regimens included antithymocyte globulin (ATG) for 0-3 doses. Pharmacologic GVHD prophylaxis was not given because the patients received a fully ex vivo TCD graft.
Patients who received palifermin received the drug as per the approved dosing schedule. 12 Three daily doses (60 mcg/kg/day) were given before transplant admission, with the third dose given no lesser than 24 h before administration of chemotherapy or radiotherapy. Starting 6 h after stem cell infusion, patients received three further daily doses of palifermin (60 mcg/kg/day).
Efficacy evaluation
Data were collected on the number of days patients required TPN and patient-controlled analgesia (PCA) with narcotics. 12, 14 Patients were placed on PCA by the transplant attending physician when patients complained of any mouth or throat pain that interfered with swallowing. The PCA was discontinued when the patient did not require 'demand doses' in the absence of a basal rate. Our practice of administering TPN is described above. In addition, length of the initial hospital stay (LOS) for transplant from the time of admission was determined for all patients.
Transplant-related toxicity evaluation
The diagnosis of GVHD was made on clinical grounds and confirmed pathologically whenever possible. Acute GVHD (aGVHD) was graded according to CIBMTR criteria. 22 Patients were evaluable for aGVHD after engraftment. Patients surviving 4100 days were evaluable for chronic GVHD (cGVHD). Chronic GVHD was classified as limited or extensive by the criteria of Sullivan.
23 NIH Consensus Criteria were not used in this study because its retrospective nature limited the data available for cGVHD grading.
Primary graft failure was defined as the absence of neutrophil recovery (X500/mL) by day 28 and BM biopsy with p5% cellularity. Secondary graft failure was defined as loss of ANC to o500/mL after primary engraftment with BM biopsy showing p5% cellularity. 18 
Biostatistics
We compared the continuous outcomes of PCA use, TPN use and LOS between palifermin recipients and non-recipients using the t-test. Linear regression models were fitted to evaluate the effect of palifermin on each of these mucositis-related outcomes, after adjusting for age, ATG use and preparative regimen (TBI-based and chemotherapy-based). Although it was not expected that ATG use would affect mucositis, it was carried over to these multivariate analyses to be consistent with the analyses for time to development of aGVHD. Competing risk analysis and multivariable competing risk regression controlling for age, ATG use and preparative regimen were used to evaluate the effect of palifermin on the time to acute and chronic GVHD. To evaluate the effect of palifermin on survival outcomes, the log-rank test was applied to OS and EFS. The Cox regression model was used for these time-to-event outcomes, adjusting for age, ATG use and preparative regimen. Table 1 details the patient characteristics. The median age at transplant was 55 years (range 19-73 years). The diagnoses were varied and are detailed in Table 1 . A total of 121 patients received TBI-based conditioning (48%, Figure 1 ). Of these patients, 77 (64%) received palifermin. Of the 130 patients who received a chemotherapy-based allo-HSCT (52%), 77 (59%) received palifermin. Nine patients received BM as their stem cell source, and the remaining patients received PBSC grafts. In all, 213 patients (85%) received ATG before their stem cell infusion, and two patients received ATG post stem cell infusion. ATG was not administered to the other 36 patients, who were all recipients of matched related donors and conditioned with TBI, thiotepa and fludarabine (n ¼ 34) or TBI, thiotepa and CY (n ¼ 2). Efficacy end points The effect of palifermin on the clinical end points studied is summarized in Table 2 . In univariate analysis, patients who received palifermin had fewer mean days on PCA (6 vs 10 days, P ¼ 0.020), fewer mean days on TPN (13 vs 16 days, P ¼ 0.010) and a shorter mean LOS (32 vs 37 days, P ¼ 0.016). After controlling for age at transplant, ATG use and preparative regimen, these differences remain significant (P ¼ 0.023, P ¼ 0.006 and P ¼ 0.014, respectively). In the analysis of patients who received TBI-based vs chemotherapy-based preparative regimens separately, the benefit of palifermin was limited to patients who received TBI (Table 3a) . For these patients, palifermin decreased the number of days on PCA (7 vs 12 days, P ¼ 0.023), TPN (13 vs 17 days, P ¼ 0.002) and the LOS (32 vs 38 days, P ¼ 0.003) in univariate analysis. In the multivariate analysis, this benefit persisted (P ¼ 0.033, Po0.001 and P ¼ 0.001, respectively). However, for recipients of the chemotherapy-based preparative regimen (Table 3b) , no benefit was observed.
RESULTS

Patient characteristics
Palifermin toxicity Side effects commonly associated with palifermin use were observed in our patient population. These toxicities were in all cases mild and resolved without any intervention once the course of palifermin was completed. Documented side effects included erythema or rash (64 patients, 42%), oral hyperplasia or discoloration (22 patients, 14%) and edema of hands and feet or eyelids (11 patients, 7%). Of the 154 patients who received palifermin, 77 patients (50%) were noted to have at least one reaction to palifermin and 18 patients (12%) had more than one reaction.
Transplant-related toxicity Consistent with our prior experience in TCD allo-HSCT, the 3-month cumulative incidence rate of grade 2-4 aGVHD was 12% (95%CI: 8-16%) and the 1-year cumulative incidence rate of cGVHD was 10% (95%CI: 6-14%). There was no observed effect of palifermin on the development of aGVHD (Figure 2a ) or cGVHD ( Figure 2b ). In addition, palifermin did not affect the rate of graft failure. In the entire cohort, two primary graft failures and four late graft failures were noted. Of the patients who received palifermin, 4/154 (2.6%) suffered graft failure. Two patients of the 97 who did not receive palifermin (2.1%) also had graft failure. (Figure 3a) or EFS (Figure 3b ). However, age at transplant was a significant prognostic factor for OS (HR 1.02, 95%CI: 1.00-1.04, P ¼ 0.05) and EFS (HR 1.02, 95%CI: 1.00-1.04, P ¼ 0.04), controlling for ATG use and preparative regimen.
DISCUSSION
Our results represent the largest published experience with palifermin in allo-HSCT recipients to date. Recognizing the limitations of a retrospective study, including possible physician bias, we are able to demonstrate for the first time that palifermin does not increase transplant-related toxicity in the allogeneic transplant setting and is efficacious following TBI-based allo-HSCT. Previous studies evaluating palifermin with allo-HSCT were limited because they were smaller in size, were focused on GVHD prevention and/or did not use palifermin at the currently approved dosing schedule. [13] [14] [15] In our study, 154 patients undergoing allo-HSCT received peritransplant palifermin. Because this was a retrospective study, we were unable to accurately report the effect of palifermin on the World Health Organization grade of mucositis. Outside of prospective studies specifically designed to assess mucositis, mucositis scoring is inconsistently recorded in the medical chart.
Clinical end points associated with mucositis that have been described in previous studies 12, 14, 15 were used, and we demonstrated a significant reduction in TPN use, PCA use and length of stay. Analyzing recipients of TBI-based and chemotherapy-based allo-HSCT separately, the benefit of palifermin was limited to recipients of TBI. In this group of patients, palifermin decreased the mean number of days patients received PCA and TPN by 5 days (P ¼ 0.033) and 4 days (Po0.001), respectively. In addition, the LOS for the transplant hospitalization in patients who received palifermin was also 6 days shorter (P ¼ 0.001). Common side effects associated with palifermin use were observed at similar rates as previously published. 12 Our study also demonstrated that palifermin administration did not increase transplant-related toxicity during allo-HSCT. In this large patient population receiving the FDA-approved dosing of palifermin, no apparent increased rate of aGVHD and cGVHD or graft failures was seen. However, as all patients received ex vivo TCD allo-grafts and ATG, it is possible that palifermin may have an effect on the development of GVHD in other settings. Furthermore, there was also no difference in OS or EFS between the two groups (P ¼ 0.704 and P ¼ 0.463, respectively).
There have been limited data supporting the use of palifermin during allogeneic transplantation. [13] [14] [15] Blazar et al. 13 reported a phase I/II dose-escalation, randomized, placebo-controlled study that evaluated the effect of palifermin on the prevention of aGVHD, based on preclinical studies that suggested that palifermin may prevent aGVHD. 24, 25 Sixty-nine patients received palifermin, whereas 31 patients received placebo. No difference in the rate of aGVHD, time to engraftment, relapse or survival was noted between the two groups, which is consistent with our data. A subgroup analysis revealed a significant decreased incidence and mean severity of mucositis in patients conditioned with CY Palifermin in allogeneic transplantation JD Goldberg et al and TBI but not with BU and CY. This study included four different dosing schedules, with eight patients receiving less and 51 patients receiving more palifermin than the current approved dose. Ten patients in the study received palifermin at the current FDA-approved dosing. Langner et al. 14 also reported a limited series on palifermin in the allo-HSCT setting. They treated 30 patients with palifermin who were undergoing allo-HSCT for leukemia and compared them with a matched historical control group. There was a decreased incidence in grade II-IV mucositis for patients who received palifermin compared with control (60% vs 80%, P ¼ 0.04). There was also a decrease in the mean duration of mucositis for patients receiving palifermin (6 vs 12 days, P ¼ 0.003), a decrease in the median total dose of opioids administered (150 mg vs 378 mg, P ¼ 0.04) and duration of TPN use (15 vs 26 days, P ¼ 0.002). No effect of palifermin on hematological recovery, the development of aGVHD or OS was noted in this small study. Similarly, Nasilowska-Adamska et al. 15 treated 53 patients transplanted for hematologic malignancies with palifermin and compared them with a matched historical control group. The benefit for mucositis prevention was confirmed, and there was no difference between the groups with regard to the development of any aGVHD. Further allogeneic transplant-specific analyses were limited because only 24 patients who received palifermin underwent allo-HSCT, whereas the remainder of the patients received an autologous transplant.
Our findings demonstrate a significant benefit for allo-HSCT recipients that can potentially impact their quality of life, as well as the complications and cost of the transplant and hospitalization.
The reduced requirement for TPN, for example, may have important implications toward decreasing infections and hepatic complications in this compromised patient population. It is possible that the impact of palifermin on TPN use would have been more significant had we initiated TPN strictly based on caloric need rather than routine, as patients with decreased oral mucositis may not have met the requirements for TPN. The decrease in the initial transplant hospitalization by almost 1 week may be expected to decrease patients' risk for developing hospital-acquired infections and may speed recovery. Importantly, the benefits of palifermin were observed exclusively in recipients of a TBI-based conditioning regimen. Palifermin did not affect our clinical end points in the cohort of patients receiving a BU-based chemotherapy preparative regimen. These findings are consistent with those of Blazar et al., 13 whose study used a different TBI-based and BU-based conditioning regimen and whose study utilized MTX as part of their GVHD prophylaxis, supporting a broad applicability to our findings. The possibility that palifermin could decrease mucositis following a different or more intense chemotherapy-based conditioning regimen, however, cannot be excluded. Further validation would be required to definitively assess whether palifermin will continue to be efficacious following administration of MTX. Although unlikely, it is possible that the initiation of vancomycin prophylaxis against oral flora at around the same time as the initiation of palifermin may confound our results, as an oral infection could potentially exacerbate mucositis. Another potential confounder of our results may be that the two cohorts of patients who received a TBI-based allo-HSCT could have different clinical outcomes. Furthermore, other dosing schedules, which have been published in non-transplant settings, 26, 27 may merit further exploration in the transplant setting.
In summary, we demonstrate in this large retrospective study that palifermin is efficacious during allo-HSCT and does not increase transplant-related toxicity in this setting. Our study represents the largest cohort of patients treated at the indicated dose, and therefore is a significant contribution to guide current clinical practice with this drug in the allo-HSCT setting. Because palifermin use is confounded with date of HSCT and other clinical factors in this retrospective study, a prospective randomized study is needed to validate these results. We are currently planning a large, multicenter prospective study evaluating the safety and efficacy of palifermin in a TBI-based myeloablative TCD allo-HSCT patient population to confirm our findings. 
